Title | Systems biology data analysis methodology in pharmacogenomics. |
Publication Type | Journal Article |
Year of Publication | 2011 |
Authors | Rodin, AS, Gogoshin, G, Boerwinkle, E |
Journal | Pharmacogenomics |
Volume | 12 |
Issue | 9 |
Pagination | 1349-60 |
Date Published | 2011 Sep |
ISSN | 1744-8042 |
Keywords | Artificial Intelligence, Drug Discovery, Drug-Related Side Effects and Adverse Reactions, Epistasis, Genetic, Genotype, Humans, Molecular Epidemiology, Pharmacogenetics, Research Design, Statistics as Topic, Systems Biology |
Abstract | Pharmacogenetics aims to elucidate the genetic factors underlying the individual's response to pharmacotherapy. Coupled with the recent (and ongoing) progress in high-throughput genotyping, sequencing and other genomic technologies, pharmacogenetics is rapidly transforming into pharmacogenomics, while pursuing the primary goals of identifying and studying the genetic contribution to drug therapy response and adverse effects, and existing drug characterization and new drug discovery. Accomplishment of both of these goals hinges on gaining a better understanding of the underlying biological systems; however, reverse-engineering biological system models from the massive datasets generated by the large-scale genetic epidemiology studies presents a formidable data analysis challenge. In this article, we review the recent progress made in developing such data analysis methodology within the paradigm of systems biology research that broadly aims to gain a 'holistic', or 'mechanistic' understanding of biological systems by attempting to capture the entirety of interactions between the components (genetic and otherwise) of the system. |
DOI | 10.2217/pgs.11.76 |
Alternate Journal | Pharmacogenomics |
PubMed ID | 21919609 |
PubMed Central ID | PMC3482399 |
Grant List | RC2 HL102419 / HL / NHLBI NIH HHS / United States 5RC2HL102419 / HL / NHLBI NIH HHS / United States U01 GM074492 / GM / NIGMS NIH HHS / United States 5R01HL083498 / HL / NHLBI NIH HHS / United States R01 HL072810 / HL / NHLBI NIH HHS / United States R01 HL083498 / HL / NHLBI NIH HHS / United States U01 HG004402 / HG / NHGRI NIH HHS / United States R03 LM009738 / LM / NLM NIH HHS / United States 5R03LM009738 / LM / NLM NIH HHS / United States 5P50GM065509 / GM / NIGMS NIH HHS / United States 5R01HL084099 / HL / NHLBI NIH HHS / United States 2U01GM074492 / GM / NIGMS NIH HHS / United States R01 HL084099 / HL / NHLBI NIH HHS / United States 5R01HL072810 / HL / NHLBI NIH HHS / United States R01 AI085014 / AI / NIAID NIH HHS / United States 1R01AI085014 / AI / NIAID NIH HHS / United States 3U01HG004402 / HG / NHGRI NIH HHS / United States 5R01HL086694 / HL / NHLBI NIH HHS / United States P50 GM065509 / GM / NIGMS NIH HHS / United States |
Systems biology data analysis methodology in pharmacogenomics.
Similar Publications
Single cell dual-omic atlas of the human developing retina. Nat Commun. 2024;15(1):6792. | .
Loss of symmetric cell division of apical neural progenitors drives DENND5A-related developmental and epileptic encephalopathy. Nat Commun. 2024;15(1):7239. | .
The DNA methylome of pediatric brain tumors appears shaped by structural variation and predicts survival. Nat Commun. 2024;15(1):6775. | .